AlphAIAlphAI — Financial news for AI agents
ibtimes.com.auOCT 232 min read$TNGX

Tango Therapeutics Stock Tumbles 16% Despite 82% Response Rate in Pancreatic Cancer Combo Trial at ESMO

Tango Therapeutics (TNGX) shares fell 16% despite presenting pancreatic cancer trial data showing an 82% response rate. The stock had risen 28% before the release. The trial tested vopimetostat with Revolution Medicines' daraxonrasib. Phase 3 plans are set for 2027. Investors may have taken profits after the stock's recent gains.

Original reporting
ibtimes.com.au
Published Oct 23, 2026, 2:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 3:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tango Therapeutics Stock Tumbles 16% Despite 82% Response Rate in Pancreatic Cancer Combo Trial at ESMO — source image
Source · ibtimes.com.au
Decision brief

The 30-second read

$TNGXBearishMed
01

Why it matters

The data were released after a period of share price rally, leading to profit‑taking and concerns about the trial's size and timeline, driving a 16% drop.

02

Market read

First‑report trial data triggered a sharp intra‑day sell‑off, highlighting market sensitivity to early‑stage oncology results.

03

What to watch

The data set is still small (22 patients) and progression‑free survival is not yet reached; investors may be over‑reacting to a short‑term price move.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Tango Therapeutics presented updated Phase 2 data at the ESMO Congress, showing an 82% tumor‑shrink response in a genetically defined pancreatic cancer cohort.

Company-level read

Ticker impact

$TNGXBearishHigh confidence
Context

Tango Therapeutics disclosed Phase 2 pancreatic cancer combo trial results with an 82% response rate, causing the stock to tumble 16% in early trading.

Expected impact

likely continued pressure as the market prices in concerns over trial size, durability and upcoming Phase 3 timing

Evidence & confidence

The stock fell sharply on the same day the data were released, indicating a strong immediate reaction that may persist until further clarification.

Market effects

Sector

Biotech investors may reassess other early‑stage oncology combos, especially PRMT5 inhibitors.

Regional

US biotech sector could see modest pullback amid heightened scrutiny of trial data.

Global

Limited to investors tracking clinical‑trial outcomes; no broader macro effect.

Counterpoint

What could challenge this read

The strong response rate and disease control could support a rebound if Phase 3 enrollment proceeds smoothly.

Key entities

  • Company
    Tango Therapeutics

    Biotech firm developing PRMT5 inhibitor vopimetostat.

  • Company
    Revolution Medicines

    Partner providing daraxonrasib for the combo.

Read at source← All news

StoryTango Therapeutics reports 82% response rate in pancreatic cancer trial and announces 2027 Phase 3 plan

Also covered by

2 outlets

Related articles

OCT 23
$TNGXMedAI 8/10

Wedbush raises Tango Therapeutics stock price target on trial data

Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.

investing.com2 min
OCT 23
$TNGXMedAI 8/10

Stifel raises Tango Therapeutics stock price target on trial data

Stifel raised its price target for Tango Therapeutics (TNGX) to $55 from $40, maintaining a Buy rating. The company's shares have surged 271% over the past year. Stifel increased its peak sales estimate to $7.1 billion, citing trial data. Tango Therapeutics announced workforce reductions and plans to focus on key therapies, with updates expected in 2027. Other analysts have also raised their price targets, with varying opinions on the stock's valuation.

investing.com2 min
OCT 23
$TNGXMedAI 8/10

Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?

Tango Therapeutics (TNGX) reported Phase 1/2 trial data for vopimetostat, showing strong efficacy in pancreatic and lung cancers when combined with Revolution Medicines' (RVMD) RAS(ON) inhibitors. The combination achieved 82% and 80% response rates in pancreatic and lung cancer patients, respectively. Tango plans a global registrational study in 2027. TNGX shares fell 10.65% to $24.95 on Friday.

finance.yahoo.com2 min
OCT 23
$TNGXHighAI 8/10

Why is Tango Therapeutics stock sliding today?

Tango Therapeutics (TNGX) fell 6.8% in pre-market trading after releasing Phase 1/2 trial results showing 82% response rate and 88% progression-free survival in pancreatic cancer patients. The decline follows a 28% stock surge ahead of the data release and coincides with broader market sell-offs. An affiliate officer's planned share sale also contributed to pressure.

investing.com1 min